Explore Goddess Protocol RxRx care

Tirzepatide

Ingredient · In our Tirzepatide Injection

Tirzepatide (the active ingredient in Zepbound and Mounjaro)

Tirzepatide acts on two gut hormone pathways at once, GLP-1 and GIP. Together they help with fullness, appetite and blood sugar. It's a newer cousin of semaglutide.1,2

Abstract prismatic satin fan, illustrative ingredient artwork
Tirzepatide

Photo is an illustration, not the medicine. Tirzepatide is made in a lab.

FDA-approved ingredient

Tirzepatide is FDA-approved for long-term weight management in adults with obesity, or overweight plus a related health condition, and for moderate to severe sleep apnea in adults with obesity, as Zepbound.1 Our tirzepatide is compounded by a licensed pharmacy, and compounded versions are not FDA-approved or reviewed by FDA for safety, effectiveness or quality.6,7

FDA-approved for this useWell studied, used off-labelEarly evidenceLittle or no human data

The studies below used FDA-approved products or other forms. Our compounded version hasn't been studied in trials, and results may differ.

What it is

After you eat, your gut releases two hormones, GLP-1 and GIP, that help your body release insulin and signal that you're full. Tirzepatide activates both. It's taken as one injection a week.1,2

Why it's in this product

It's the active ingredient in our Tirzepatide Injection. The FDA-approved version has been tested in large trials, described below. Your clinician decides if it fits.3,4

Tirzepatide Injection

What the studies in people show

  • Randomized trial15% to 21% average weight loss over 72 weeksIn 2,539 adults with obesity or overweight (without diabetes), weekly FDA-approved Zepbound (tirzepatide) led to average weight loss of 15.0% at 5 mg, 19.5% at 10 mg and 20.9% at 15 mg, compared with 3.1% on placebo.3
  • Randomized trialLess type 2 diabetes over three yearsAmong 1,032 people in that trial who also had prediabetes, 1.3% of those on FDA-approved tirzepatide were diagnosed with type 2 diabetes over 176 weeks, compared with 13.3% on placebo.4
  • Randomized trialBetter blood sugar in type 2 diabetesIn 478 adults with type 2 diabetes, FDA-approved Mounjaro (tirzepatide) lowered HbA1c (a three-month blood sugar average) by about 1.9 to 2.1 points in 40 weeks, compared with almost no change on placebo.5

What we don't know yet

These trials used brand-name tirzepatide, so they don't directly prove that compounded versions perform the same way.7 As with semaglutide, much of the weight tends to return after stopping, and the best long-term plan is still being studied.

Safety, in plain English

The most common side effects are nausea, diarrhea, vomiting, constipation, indigestion and belly pain, usually worst while the dose is being raised.1 Rarer but serious risks on the label include pancreatitis, gallbladder problems and kidney injury from dehydration. Tirzepatide carries a boxed warning because it caused thyroid C-cell tumors in rats, and it isn't used by people with a personal or family history of medullary thyroid cancer or MEN 2.1

One that matters in midlife: tirzepatide can make birth control pills less reliable, so the label advises switching to a non-pill method, or adding a barrier method, for 4 weeks after starting and after each dose increase.1 FDA has also received adverse event reports linked to compounded tirzepatide doses beyond the label.6 A licensed clinician decides whether tirzepatide is appropriate for you, and exploring it here never means you'll get a prescription.

Curious about Tirzepatide Injection?

Start with a free assessment. A licensed clinician reviews your health history and decides whether treatment is appropriate. No pressure, and no prescription unless it makes sense for you.

See Tirzepatide InjectionHow care works

Sources

  1. U.S. National Library of Medicine, DailyMed. Zepbound (tirzepatide) injection: prescribing information. DailyMed
  2. U.S. National Library of Medicine, DailyMed. Mounjaro (tirzepatide) injection: prescribing information. DailyMed
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205-216. PubMed 35658024
  4. Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392:958-971. PubMed 39536238
  5. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Lancet. 2021;398:143-155. PubMed 34186022
  6. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026). FDA
  7. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. FDA

Sources checked November 8, 2026. This page is general education, not medical advice, and it doesn't mean any treatment is right for you. Photos: Unsplash (Johnny Brown).